Myeloma Patients Europe (MPE) recently held the first face-to-face meeting of the Advocate Development Programme (ADP) in Stockholm, Sweden during the European Haematology Association (EHA) Annual Congress 2018. Continue reading
MPE is inviting members to express their interest in participating in a small pilot on patient information for newly diagnosed myeloma patients.
As part of this pilot, MPE will be adapting and translating an Infopack for newly diagnosed patients (created by Myeloma UK) for use in small group of European countries. The Infopack provides information that patients may need to know following the diagnosis of myeloma and provides practical tips.
The European Commission has issued a legislative proposal to the European Council and European Parliament on further integration of health technology assessment (HTA) in the EU.
Myeloma Patients Europe will hold an online webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United States) in December 2017.
The talk will be given by Dr María Victoria Mateos, Associate Professor of Hematology and Consultant. Physician of the Haematology Department at the University Hospital of Salamanca, Spain. Continue reading
As part of the Advocate Development Programme (ADP), MPE is organising an online webinar about science in patient advocacy. Although the webinars held within the ADP are usually open only to our ADP trainees, on this occasion we would like to invite to the webinar all our members and patient advocates interested in science. The webinar “Science in patient advocacy” will be given by Bettina Ryll, chair of the ESMO Patient Advocates Working Group (PAWG) and founder of the Melanoma Patient Network Europe (MPNE).
The 59th American Society of Hematology (ASH) Annual Meeting will take place from 9 – 12 December in Atlanta, Georgia, United States (US). Myeloma Patients Europe (MPE) will be attending the meeting, alongside thousands of leading doctors, researchers and patient advocates in the field of blood cancer (hematology). Below we explain ASH and the importance of the meeting to patient advocates.